Epoch Investment Partners Inc. Sells 47,960 Shares of Gilead Sciences, Inc. $GILD

Epoch Investment Partners Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 549,365 shares of the biopharmaceutical company’s stock after selling 47,960 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Gilead Sciences were worth $76,565,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences in the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC increased its holdings in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the period. Quattro Advisors LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $26,000. Wealth Preservation Advisors LLC grew its position in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC purchased a new position in Gilead Sciences in the fourth quarter worth $28,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on GILD. Morgan Stanley cut their price objective on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $146.00 to $127.00 in a research note on Tuesday. Finally, Citigroup lifted their price target on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $158.33.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the transaction, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the transaction, the insider owned 124,234 shares in the company, valued at $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 77,000 shares of company stock worth $9,978,740. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $129.31 on Friday. The business’s 50 day moving average price is $129.55 and its 200 day moving average price is $135.50. The company has a market cap of $160.55 billion, a price-to-earnings ratio of 17.62 and a beta of 0.32. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the company earned $1.81 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post -0.77 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.